News | August 28, 2008

Research Suggests Statin Therapy is Underused for Elderly Patients with Atherosclerosis

August 29, 2008 - Statins, a group of drugs used to lower cholesterol levels in people with or at risk of having cardiovascular disease, should be used more frequently to combat the adverse cardiovascular outcomes from atherosclerosis, according to new research published in the September 2008 issue of the Journal of Vascular Surgery.

Atherosclerosis (hardening of the arteries) is the leading cause of death of adults worldwide and is caused when fatty substances collect in the inner lining of artery walls.

In a 10-year population-based study (from 1995 to 2005), of 343,154 elderly patients in Ontario, Canada, researchers discovered an important care gap in the management of older patients with symptomatic atherosclerosis due to the suboptimal prescription of statins. Sixty-nine percent of the patients had coronary artery disease (CAD), 34 percent had cerebrovascular disease (CVD) and 7 percent had peripheral arterial disease (PAD). About 46 percent of the patients were women, and mean patient age was 77.1 years.

The percentage of all atherosclerotic patients who were treated with statins increased from 9.8 percent to 55.3 percent. When broken down by each condition, the percentages of patients given statins were as follows: those with CAD jumped 11.8 percent to 61.2 percent; patients with CVD increased from 5.3 percent to 41.2 percent; and those with PAD rose from 6.8 percent to 43.3 percent.

"Even though the use of statin therapy in elderly patients with symptomatic atherosclerosis has increased substantially during the past decade, our study showed many patients remain untreated," said Subodh Verma, M.D., Ph.D., a cardiac surgeon at St. Michael's Hospital, University of Toronto and the Canada Research Chair in Atherosclerosis.

He added that suboptimal use was greatest among patients with PAD or CVD, or both, and lowest in patients with CAD.

Given the heightened risk of cardiovascular adverse outcomes in patients with atherosclerosis, researchers believe their results have important and immediate implications. "This was especially evident in patients with CVD and PAD with data from January to March in 2004, that indicated that less than 50 percent of these patients were on statins," said Dr. Verma.

Strong evidence supports the management of atherosclerosis with statins, according to Dr. Verma. He pointed to a recent study involving more than 90,000 participants that indicated for every slight reduction (1 millimole per litre) in low-density lipoprotein (LDL) cholesterol, there was also reduction of about 23 percent in the risk of heart attacks or coronary-related mortality, a 24 percent reduction in the need for coronary revascularization, and a 17 percent reduction in the rate of fatal or non-fatal stroke.

Co-investigator Mohammed Al-Omran, M.D., MSc, an assistant professor in the division of vascular surgery, King Saudi University, Riyadh, Saudi Arabia and a scientist at St. Michael’s Hospital, University of Toronto, noted the results of the current study support current literature and underscore the inequities in the use of risk reduction therapies for patients with PAD compared with patients with CAD.

"Our findings highlight the treatment care gaps in patients with atherosclerosis and may be useful for guiding medical interventions, focusing continuing medical education programs, encouraging active discussions on risk reduction therapies at scientific meetings, and other educational outreach programs that aim to bring physicians' practice into agreement with current guidelines for cardiovascular risk reduction,” said Dr. Al-Omran

For more information:,

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init